GlassScriptPhysician profile
Caroline Dawson
NPI 1578598322
$1,398.02
in general payments reported to CMS, 2019-2025
15 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $24.69 · 2023: $136 · 2024: $269 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $559.98 | 2023-2025 | Airsupra, Andexxa, Farxiga |
| Abbvie INC. | $217.40 | 2021-2025 | |
| Novo Nordisk INC | $135.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $82.02 | 2024-2025 | Mounjaro, Zepbound |
| Edwards Lifesciences Corporation | $64.23 | 2021 | |
| Sumitomo Pharma America, INC. | $63.78 | 2025 | Gemtesa |
| Amgen INC. | $56.57 | 2023-2025 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.66 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $41.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $31.19 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.12 | 2025 | Opsumit, Uptravi |
| Neurocrine Biosciences, INC. | $22.64 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.08 | 2025 | Eliquis |
| Pfizer INC. | $16.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.